ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
Bone Mineral Density: Clinical Relevance and Quantitative Assessment.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Comparative efficacy and safety of anti-osteoporotic therapies for kidney transplant recipients: a systematic review and network meta-analysis.Frontiers in endocrinology · 2025Pooled it
- What can we learn about bone density in COPD patients from a chest CT? A systematic review.Croatian medical journal · 2024Pooled it
- Effects of a Plant-Based Multi-StrainNutrients · 2026Trial
- Efficacy of zoledronic acid in peri-menopausal women with osteopenia.Journal of bone and mineral metabolism · 2026Trial
- Observation of the Short-term Efficacy of Technetium-99 Conjugated with Methylene Diphosphonate Combined Therapy in the Treatment of Postmenopausal Osteoporosis.Combinatorial chemistry & high throughput screening · 2024Trial
- AI for Opportunistic Identification of BMD and Bone Microarchitecture: A Narrative Review.Calcified tissue international · 2026Review
- Mechanistic Insights into Milk Minerals Driving Bone Development and Mineralization in Growing Rats.Nutrients · 2026Article
- Importance of Recognizing Renal Tubular Disorders as a Cause of Bone Hypomineralization and Fractures in Adults.Diagnostics (Basel, Switzerland) · 2026Review
- Generalizable framework for multi-site bone density prediction using non-dominant wrist optical biomarkers.Biomedical optics express · 2026Article
- Combined Supplementation OF Magnesium AND Boron Ameliorate Menopause-Associated Osteogenic Disturbances in Ovariectomized Rats.Biological trace element research · 2026Article
- A Longitudinal Evaluation of Bone Mineral Density Across a Macrocycle in Highly Trained Female Athletes: A Systematic Review.Sports (Basel, Switzerland) · 2026Review
- Nonlinear association between physical activity and bone mineral density in adolescents.Pediatric research · 2026Article
- Postoperative osteoporosis therapy and risk of re-fracture in elderly patients with hip fractures: a multicenter retrospective cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Identification of a novel KISS1R (GPR54) gene variant (c.505+2T>G) in a patient with congenital hypogonadotropic hypogonadism: A case report and literature review.Experimental and therapeutic medicine · 2026Article
- Opportunistic Osteoporosis Screening in Breast Cancer Using AI-Derived Vertebral BMD from Routine CT: Validation Against QCT and Multivariable Diagnostic Modeling.Journal of clinical medicine · 2026Article
- Development and validation of a nomogram predicting osteoporosis risk in rheumatoid arthritis.Frontiers in medicine · 2026Article
- Association between dietary vitamin B12 intake and bone mineral density in adolescents.Pediatric research · 2026Article
- Nonlinear Association of Estimated Pulse Wave Velocity With Bone Health Outcomes: Evidence From the NHANES Database.International journal of endocrinology · 2026Article
- Cognitive decline and reduced bone mineral density under the bone-brain axis: mechanistic insights and imaging evaluation strategies.Frontiers in aging neuroscience · 2026Review
- Photon-Counting CT in Musculoskeletal Radiology: Technical Principles, Clinical Applications, and Future Directions.Journal of the Belgian Society of Radiology · 2026Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Bone mineral density (BMD) measurement by dual-energy x-ray absorptiometry (DXA) is an internationally accepted standard-of-care screening tool used to assess fragility-fracture risk. Society guidelines have recommended which populations may benefit from DXA screening and the use of the fracture risk assessment tool (FRAX) to guide decisions regarding pharmacologic treatment for osteoporosis. According to the U.S. National Osteoporosis Foundation guidelines, postmenopausal women and men at least 50 y old with osteopenic BMD warrant pharmacologic treatment if they have a FRAX-calculated 10-y probability of at least 3% for hip fracture or at least 20% for major osteoporotic fracture. Patients with osteoporosis defined by a clinical event, namely a fragility fracture, or with an osteoporotic BMD should also be treated. Patients who are treated for osteoporosis should be monitored regularly to track expected gains in BMD by serial DXA scans. With some drug therapies, BMD targets can be reached whereby further improvements in BMD are not associated with further reductions in fracture risk. Although reaching this target might suggest a stopping point for therapy, the reversibility of most treatments for osteoporosis, except for the bisphosphonates, has dampened enthusiasm for this approach. In the case of denosumab, it is now apparent that stopping therapy at any point can lead to an increase in multiple-fracture risk. For patients who do not respond to antiosteoporosis pharmacologic therapy with an improvement in BMD, or who have an incident fragility fracture on therapy, secondary causes of osteoporosis or non-compliance with medical therapy should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.